HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
3,010.00
-165.00 (-5.20%)
Oct 12, 2026, 3:30 PM KST
HLB Therapeutics Revenue
HLB Therapeutics had revenue of 12.56B KRW in the quarter ending June 30, 2026, a decrease of -19.87%. This brings the company's revenue in the last twelve months to 64.45B, up 5.25% year-over-year. In the year 2025, HLB Therapeutics had annual revenue of 69.56B with 26.63% growth. That makes HLB Therapeutics the 28,228th largest company in the world by revenue and 1,719th in South Korea.
Revenue (ttm)
64.45B
Revenue Growth
+5.25%
P/S Ratio
4.12
Revenue / Employee
1.32B
Employees
49
Market Cap
265.30B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 69.56B | 14.63B | 26.63% |
| Dec 31, 2024 | 54.93B | 2.34B | 4.45% |
| Dec 31, 2023 | 52.59B | 10.19B | 24.03% |
| Dec 31, 2022 | 42.40B | -1.18B | -2.72% |
| Dec 31, 2021 | 43.59B | 656.63M | 1.53% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Bioneer | 345.88B |
| Medy-Tox | 251.08B |
| GC Cell | 162.00B |
| MEDIPOST | 74.84B |
| GC Genome | 32.64B |
| SillaJen | 10.77B |
| Genomictree | 2.95B |